CY1111001T1 - Ουρικη οξειδαση - Google Patents

Ουρικη οξειδαση

Info

Publication number
CY1111001T1
CY1111001T1 CY20101101175T CY101101175T CY1111001T1 CY 1111001 T1 CY1111001 T1 CY 1111001T1 CY 20101101175 T CY20101101175 T CY 20101101175T CY 101101175 T CY101101175 T CY 101101175T CY 1111001 T1 CY1111001 T1 CY 1111001T1
Authority
CY
Cyprus
Prior art keywords
urinary
proteins
uricase
oxidation
relates
Prior art date
Application number
CY20101101175T
Other languages
English (en)
Inventor
Michael Hershfield
Susan J Kelly
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of CY1111001T1 publication Critical patent/CY1111001T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12N9/0048—Uricase (1.7.3.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται, γενικά, σε πρωτεΐνες ουρικής οξειδάσης (ουρικάσης) και μόρια νουκλεϊκού οξέος που κωδικοποιούν τις ίδιες. Συγκεκριμένα, η εφεύρεση αναφέρεται σε πρωτεΐνες ουρικάσης που είναι ειδικά χρήσιμες ως, για παράδειγμα, ενδιάμεσα για παραγωγή βελτιωμένων τροποποιημένων πρωτεϊνών ουρικάσης με μειωμένη ανοσογονικότητα και αυξημένη βιοδιαθεσιμότητα.
CY20101101175T 1998-08-06 2010-12-21 Ουρικη οξειδαση CY1111001T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9548998P 1998-08-06 1998-08-06
EP99938996A EP1100880B1 (en) 1998-08-06 1999-08-05 Urate oxidase

Publications (1)

Publication Number Publication Date
CY1111001T1 true CY1111001T1 (el) 2015-06-11

Family

ID=22252247

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101101175T CY1111001T1 (el) 1998-08-06 2010-12-21 Ουρικη οξειδαση

Country Status (23)

Country Link
US (1) US7056713B1 (el)
EP (2) EP2277998B1 (el)
JP (3) JP2002524053A (el)
KR (1) KR100841634B1 (el)
CN (2) CN101280293B (el)
AT (1) ATE483797T1 (el)
AU (1) AU766421B2 (el)
BR (1) BRPI9913360B8 (el)
CA (1) CA2337967C (el)
CY (1) CY1111001T1 (el)
CZ (1) CZ304223B6 (el)
DE (1) DE69942834D1 (el)
DK (1) DK1100880T3 (el)
ES (1) ES2352451T3 (el)
HK (3) HK1037214A1 (el)
HU (1) HU229774B1 (el)
IL (3) IL141221A0 (el)
NZ (1) NZ509633A (el)
PL (1) PL207369B1 (el)
PT (1) PT1100880E (el)
RU (1) RU2290439C2 (el)
WO (1) WO2000008196A2 (el)
ZA (1) ZA200100974B (el)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060188971A1 (en) * 1998-08-06 2006-08-24 Duke University Urate oxidase
AU770014B2 (en) * 1998-08-06 2004-02-12 Duke University Peg-urate oxidase conjugates and use thereof
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
ES2361190T3 (es) 1998-08-06 2011-06-14 Mountain View Pharmaceuticals, Inc. Conjugados de peg-oxidasa de urato y su uso.
EP2277998B1 (en) * 1998-08-06 2016-04-20 Duke University Urate oxidase
CN100371439C (zh) * 2003-04-07 2008-02-27 北京双鹭药业股份有限公司 一种重组假丝酵母尿酸氧化酶的制备方法
CN100334207C (zh) * 2004-04-27 2007-08-29 杭州北斗生物技术有限公司 一种黄曲霉尿酸氧化酶的制备方法
AU2011257764B2 (en) * 2005-04-11 2012-04-05 Horizon Therapeutics Usa, Inc. A variant form of urate oxidase and use thereof
WO2006110761A2 (en) 2005-04-11 2006-10-19 Savient Pharmaceuticals, Inc. A variant form of urate oxidase and use thereof
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
CZ2007695A3 (cs) * 2005-04-11 2008-02-27 Savient Pharmaceuticals, Inc. Variantní formy urátoxidázy a jejich použití
HU230758B1 (hu) * 2006-04-12 2018-03-28 Crealta Pharmaceuticals LLC 100% Fehérjék tisztítása kationos felületaktív anyaggal
CN101402688B (zh) * 2008-11-18 2011-04-20 中国人民解放军军事医学科学院生物工程研究所 一种融合蛋白及其编码基因与应用
BRPI1013484B1 (pt) 2009-03-24 2019-08-27 Meito Sangyo Kk protease, dna, vetor de expressão, célula transformada, e, método para produzir uma protease
SG176897A1 (en) 2009-06-25 2012-01-30 Savient Pharmaceuticals Inc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
CN102051348B (zh) 2009-10-27 2012-10-03 重庆富进生物医药有限公司 人源化重组尿酸酶及其突变体
RU2460793C2 (ru) * 2010-01-15 2012-09-10 Закрытое акционерное общество "Научно-исследовательский институт "Аджиномото-Генетика" (ЗАО АГРИ) Способ получения l-аминокислот с использованием бактерий семейства enterobacteriaceae
WO2011127393A2 (en) 2010-04-08 2011-10-13 Georgia Tech Research Corporation Variants of ancestral uricases and uses thereof
CN102634492B (zh) 2011-02-14 2015-06-10 重庆富进生物医药有限公司 聚乙二醇化犬源尿酸氧化酶类似物及其制备方法和应用
CN102757945B (zh) * 2011-04-28 2015-03-18 杭州俊丰生物工程有限公司 人尿酸氧化酶蛋白及其制备方法和其聚乙二醇结合物
CN102260653B (zh) * 2011-06-30 2013-04-03 荣俊 一种peg化重组猪-人尿酸氧化酶融合蛋白的制备及应用方法
EP2986720B1 (en) * 2013-04-17 2017-09-06 Council of Scientific & Industrial Research Uricase mutants
CN103834623B (zh) * 2014-02-11 2017-11-07 中国药科大学 具有催化活性的人源尿酸氧化酶
CN104388467A (zh) * 2014-10-27 2015-03-04 李长贵 一种构建自发性高尿酸血症小鼠模型的方法及其用途
BR112017024212A2 (pt) 2015-05-15 2018-07-17 Medimmune Llc sequências de uricases melhoradas e métodos de tratamento
CN106554948B (zh) * 2015-09-29 2019-06-25 上海生物制品研究所有限责任公司 突变型尿酸酶、peg修饰的突变型尿酸酶及其应用
CN108103079B (zh) * 2017-06-20 2021-07-13 北京锦篮基因科技有限公司 一种高尿酸血症的基因治疗药物
CN109554376B (zh) * 2018-11-13 2022-03-22 广西大学 一种碱性尿酸氧化酶及其在检测试剂盒和降低食品中尿酸的应用
CN111088268B (zh) * 2019-03-05 2022-08-02 北京锦篮基因科技有限公司 一种高尿酸血症的基因治疗药物
AU2020276510B2 (en) 2019-05-10 2024-08-01 Hangzhou Grand Biologic Pharmaceutical Inc. Polyethylene glycol-modified urate oxidase
CN112646790A (zh) * 2019-10-11 2021-04-13 上海君实生物医药科技股份有限公司 改进的尿酸酶及其用于治疗高尿酸血症的方法
CN111920942A (zh) * 2020-08-24 2020-11-13 深圳前海鹰岗生物科技有限公司 一种用于快速溶解痛风石的聚合物微针及制备方法和应用
WO2022095973A1 (zh) 2020-11-05 2022-05-12 杭州远大生物制药有限公司 尿酸氧化酶制剂及其应用
CN114438047A (zh) 2020-11-05 2022-05-06 重庆派金生物科技有限公司 制备聚乙二醇修饰的尿酸氧化酶的方法
CN112852772A (zh) * 2021-01-19 2021-05-28 中国科学院过程工程研究所 一种基于分子内交联和聚乙二醇修饰的尿酸氧化酶及其制备方法
CN112662640A (zh) * 2021-01-28 2021-04-16 中国药科大学 一种具有催化活性的尿酸氧化酶
CN113244412B (zh) * 2021-06-25 2021-10-26 深圳市瑞吉生物科技有限公司 一种基于mRNA剂型的治疗高尿酸血症或痛风的药物及其制备方法
AU2022340814A1 (en) * 2021-09-01 2024-02-15 Ginkgo Bioworks, Inc. Recombinant cells for treating diseases associated with uric acid and methods of use thereof
WO2024138370A1 (zh) * 2022-12-27 2024-07-04 北京炫景瑞医药科技有限公司 一种治疗高尿酸相关疾病的核酸药物及其制备方法和用途
CN118360300A (zh) * 2023-01-10 2024-07-19 优环(苏州)生物医药科技有限公司 一种表达尿酸氧化酶的环状rna、制备方法及应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE279486C (el)
US3613231A (en) 1969-07-25 1971-10-19 Paul F Pugh Method for manufacturing high voltage cable systems
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE3126759A1 (de) 1981-07-07 1983-01-27 Boehringer Mannheim Gmbh, 6800 Mannheim Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5075216A (en) 1988-09-23 1991-12-24 Cetus Corporation Methods for dna sequencing with thermus aquaticus dna polymerase
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5382518A (en) 1989-07-13 1995-01-17 Sanofi Urate oxidase activity protein, recombinant gene coding therefor, expression vector, micro-organisms and transformed cells
US5286637A (en) 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
US5653974A (en) 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
AU6240494A (en) 1993-02-16 1994-09-14 Enzon, Inc. Ribosome inactivating protein compositions having reduced antigenicity
WO1995000162A1 (en) 1993-06-21 1995-01-05 Enzon, Inc. Site specific synthesis of conjugated peptides
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
WO1996017929A1 (en) 1994-12-07 1996-06-13 Novo Nordisk A/S Polypeptide with reduced allergenicity
JPH09154581A (ja) 1995-12-05 1997-06-17 Asahi Chem Ind Co Ltd ウリカーゼを生産する実質上純粋な微生物
WO1998035026A1 (en) 1997-02-06 1998-08-13 Novo Nordisk A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
EP2277998B1 (en) * 1998-08-06 2016-04-20 Duke University Urate oxidase
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
AU770014B2 (en) 1998-08-06 2004-02-12 Duke University Peg-urate oxidase conjugates and use thereof
ES2361190T3 (es) 1998-08-06 2011-06-14 Mountain View Pharmaceuticals, Inc. Conjugados de peg-oxidasa de urato y su uso.

Also Published As

Publication number Publication date
PL207369B1 (pl) 2010-12-31
IL197339A (en) 2015-02-26
EP1100880A2 (en) 2001-05-23
EP1100880B1 (en) 2010-10-06
EP2277998A1 (en) 2011-01-26
EP2277998B1 (en) 2016-04-20
CZ304223B6 (cs) 2014-01-15
US7056713B1 (en) 2006-06-06
HK1037214A1 (en) 2002-02-01
JP2013215199A (ja) 2013-10-24
WO2000008196A3 (en) 2000-03-30
KR20010053633A (ko) 2001-06-25
CN101280293A (zh) 2008-10-08
IL141221A0 (en) 2002-03-10
HUP0103205A2 (hu) 2001-12-28
CN101280293B (zh) 2013-09-11
AU5336599A (en) 2000-02-28
CA2337967C (en) 2011-11-01
ATE483797T1 (de) 2010-10-15
BR9913360B1 (pt) 2013-09-24
AU766421B2 (en) 2003-10-16
CA2337967A1 (en) 2000-02-17
JP5721954B2 (ja) 2015-05-20
IL197339A0 (en) 2011-07-31
PL346222A1 (en) 2002-01-28
CN1322243A (zh) 2001-11-14
CZ2001466A3 (cs) 2001-07-11
ZA200100974B (en) 2002-06-26
BRPI9913360B8 (pt) 2021-05-25
NZ509633A (en) 2003-04-29
PT1100880E (pt) 2011-01-13
HUP0103205A3 (en) 2006-01-30
JP2002524053A (ja) 2002-08-06
EP1100880A4 (en) 2002-04-17
IL141221A (en) 2010-06-16
KR100841634B1 (ko) 2008-06-26
HK1125402A1 (en) 2009-08-07
DE69942834D1 (de) 2010-11-18
DK1100880T3 (da) 2011-01-24
HU229774B1 (en) 2014-07-28
WO2000008196A9 (en) 2000-07-13
RU2290439C2 (ru) 2006-12-27
JP2010158244A (ja) 2010-07-22
HK1153508A1 (zh) 2012-03-30
BR9913360A (pt) 2001-07-03
WO2000008196A2 (en) 2000-02-17
ES2352451T3 (es) 2011-02-18

Similar Documents

Publication Publication Date Title
CY1111001T1 (el) Ουρικη οξειδαση
ATE310090T1 (de) Gereinigte coprinus laccasen und nukleinsäuren welche dafür kodieren
DE69725861D1 (de) Katalytische nukleinsäuren und deren medizinische verwendung
HUP0203704A2 (hu) L-Pankolakton hidroláz és eljárás D-pantolakton előállítására
ATE286126T1 (de) Glialmitogene faktoren, ihre herstellung und verwendung
DE60023870D1 (de) Verfahren zur herstellung von 3-aryloxy-3-arylpropylamine und deren zwischenprodukte
DE69943286D1 (de) Fluoreszierende proteine aus nicht-biolumineszenten arten der klasse anthozoa, gene die diese proteine kodieren und deren verwendungen
ATE469911T1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
CY1109207T1 (el) Διαδικασια εχινοκανδινης
WO2002014485A3 (en) Kallikrein gene
DK1165759T3 (da) Polypeptider, der har forgrenende enzymaktivitet, og nukleinsyrer, der koder for samme
DE60229050D1 (de) Verfahren zur herstellung von ascorbinsäurezwischenprodukten in wirtszellen
DK1117798T3 (da) Fungal transskriptionel aktivator egnet ved fremgangsmåder til produktion af polypeptider
ATE369442T1 (de) In vitro evolution von nukleinsäuren und kodierten polypeptiden
ATE427959T1 (de) Gereinigtes sr-p70 protein
DE50110723D1 (de) Isolierte luziferasen sowie deren verwendung
DE69809930D1 (de) Isolierung und verwendung von nukleinsäuremolekülen, welche für mitglieder der ssx-familie kodieren
ATE403730T1 (de) Gene, die fuer kohlenstoffmetabolismus- und energieproduktions-proteine codieren
KR20040053279A (ko) 스트레스 저항성 및 내성 단백질을 코딩하는 유전자
ATE454401T1 (de) Il-18bp promoter herstellung und verwendung
WO2003040357A3 (de) Gene die fuer phosphoenolpyruvat-zucker-phosphotransferase proteine codieren
ATE430191T1 (de) Überexprimierte und gereinigte aspergillus ficuum oxidase und nukleinsäuren die für sie kodieren
CY1112104T1 (el) Μεθοδος για την προετοιμασια ενος παρασκευασματος πρωτεϊνης που στεγνωνει με κυλινδρο